Search

Your search keyword '"Altenbuchinger M"' showing total 2 results
Start Over Author "Altenbuchinger M" Journal leukemia
2 results on '"Altenbuchinger M"'

1. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.

Author

Jachimowicz RD, Klapper W, Glehr G, Müller H, Haverkamp H, Thorns C, Hansmann ML, Möller P, Stein H, Rehberg T, von Tresckow B, Reinhardt HC, Borchmann P, Chan FC, Spang R, Scott DW, Engert A, Steidl C, Altenbuchinger M, and Rosenwald A

Subjects
Adolescent, Adult, Bleomycin therapeutic use, Chemokine CCL17 genetics, Chemokine CCL17 metabolism, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Etoposide therapeutic use, Female, Gene Expression Profiling methods, Hodgkin Disease genetics, Humans, Ki-1 Antigen genetics, Ki-1 Antigen metabolism, Male, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prednisone therapeutic use, Procarbazine therapeutic use, Receptor, Platelet-Derived Growth Factor alpha genetics, Receptor, Platelet-Derived Growth Factor alpha metabolism, Survival Rate, Transcriptome, Treatment Outcome, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease drug therapy, Hodgkin Disease pathology
Published
2021
Full Text
View/download PDF

2. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Author

Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, and Spang R

Subjects
Female, Humans, Lymphoma, Large B-Cell, Diffuse metabolism, Lymphoma, Non-Hodgkin metabolism, Macrophages metabolism, Male, Middle Aged, Prognosis, Prospective Studies, Proto-Oncogene Proteins c-myc metabolism, Tumor Microenvironment physiology, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Non-Hodgkin pathology, Macrophages pathology
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a disease with heterogeneous outcome. Stromal signatures have been correlated to survival in DLBCL. Their use, however, is hampered by the lack of assays for formalin-fixed paraffin-embedded material (FFPE). We constructed a lymphoma-associated macrophage interaction signature (LAMIS) interrogating features of the microenvironment using a NanoString assay applicable to FFPE. The clinical impact of the signature could be validated in a cohort of 466 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Patients with high expression of the signature (LAMIS high ) had shorter EFS, PFS, and OS. Multivariate analyses revealed independence from IPI factors in EFS (HR 1.7, 95% CI 1.2-2.4, p-value = 0.001), PFS (HR 1.8, 95% CI 1.2-2.5, p-value = 0.001) and OS (HR 1.8, 95% CI 1.3-2.7, p-value = 0.001). Multivariate analyses adjusted for the IPI factors showed the signature to be independent from COO, MYC rearrangements and double expresser status (DE). LAMIS high and simultaneous DE status characterized a patient subgroup with dismal prognosis and early relapse. Our data underline the importance of the microenvironment in prognosis. Combined analysis of stromal features, the IPI and DE may provide a new rationale for targeted therapy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results